COMMENTING ON the ALCYONE trial for The ASCO Post, Keith Stewart, MB, ChB, the Carlson and Nelson Endowed Director of the Center for Individualized Medicine at the Mayo Clinic, Rochester, Minnesota, said, “Daratumumab added to a combination of drugs that we don’t use much anymore in the United States showed quite a substantial advantage, and this benefit started early. We are pretty confident that outcomes will be even better with newer [backbone induction] regimens.”
Dr. Stewart noted that results from more contemporary front-line regimens are already coming in. In a phase Ib study of 22 patients presented at the 2017 ASCO Annual Meeting,1 the addition of daratumumab to carfilzomib (Kyprolis), lenalidomide (Revlimid), and dexamethasone elicited responses in 100% of patients, without adversely impacting stem cell collection.1
“This was early, in only about 20 patients, but the preliminary data are strong. We are pretty convinced that daratumumab is highly effective. The findings from ALCYONE will presumably allow the company to file with the [U.S. Food and Drug Administration] for regulatory approval in the front-line setting,” he said. ■
DISCLOSURE: Dr. Stewart reported no conflicts of interest.
1. Jakubowiak AJ, Chari A, Lonial S, et al: Daratumumab in combination with carfilzomib, lenalidomide, and dexamethasone (KRd) in patients with newly diagnosed multiple myeloma (MMY1001): An open-label, phase 1B study. 2017 ASCO Annual Meeting. Abstract 8000. Presented June 4, 2017.
FOR NEWLY DIAGNOSED multiple myeloma patients not eligible for transplant, the addition of the anti-CD38 monoclonal antibody daratumumab (Darzalex) to subcutaneous bortezomib (Velcade), melphalan, and prednisone (VMP) reduced the risk of disease progression or death by 50%, the phase III ALCYONE...